Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis - Top-Institutions - MDSpire

Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis

  • By

  • Hui Zhao

  • Lei Luo

  • Wan-Ming Jia

  • April 21, 2026

  • 0 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Pediatric Allergy and Immunology
    • Immunology
    • Clinical Trials
  • #2

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Allergy and Immunology
    • Dermatology
  • #3

    Johns Hopkins Children's Center
    Johns Hopkins Children's Center

    Baltimore, MD

    Key Differentiators

    • Pediatric Allergy and Immunology
    • Clinical Immunology
  • #4

    Second Hospital of Hebei Medical University
    Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei

    Key Differentiators

    • Pediatric Allergy and Immunology
  • #5

    Massachusetts General Hospital for Children
    Massachusetts General Hospital for Children

    Boston, MA

    Key Differentiators

    • Pediatric Allergy and Immunology

Original Source(s)

Related Content